WiseTech Lifts Dividend, Flags More Growth as Fiscal Year Profit Rises 15%
By Stuart Condie
SYDNEY--WiseTech Global raised its dividend and flagged earnings growth over its current fiscal year after the logistics software provider lifted annual profit by 15%.
The ASX-listed company on Wednesday reported an underlying net profit for the 12 months through June of 283.5 million Australian dollars (US$191.3 million), compared with A$247.6 million a year earlier. Statutory revenue rose by 28% to A$1.04 billion.
The board declared a final dividend of 9.2 Australian cents, compared with 8.4 Australian cents a year earlier.
Including one-off items, statutory profit rose by 24% to A$262.8 million. Earnings before interest, tax, depreciation and amortization, or Ebitda, rose by 28% to A$495.6 million.
The average analyst forecast was for an underlying net profit of A$272.5 million off revenue of A$1.06 billion, according to data compiled by FactSet. Analysts expected adjusted Ebitda of A$489 million.
WiseTech's full-year Ebitda margin of 48% beat its improved guidance range of 44-46%. It expects fiscal 2025 Ebitda growth of 33-41% at a margin of 51-52%.
Write to Stuart Condie at stuart.condie@wsj.com
(END) Dow Jones Newswires
August 20, 2024 18:56 ET (22:56 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks